1A) The pet supplements market is expanding extremely fast, and both regulation and science are still catching up. As a result, we see meaningful gaps on two fronts. First, regulatory gaps: the “framework” for what can be used and how it can be positioned is less mature than in the human space, especially when it comes to botanicals and standardized extracts. Second, scientific gaps: in human supplements, we can often rely on a long history of traditional use, supported in many countries by well-established categories (e.g., herbal medicinal products in parts of Europe, or deeply rooted traditional medicine systems such as in China or India). Animals have historically also relied on plants and herbs, but we do not have an equally structured, modern scientific mapping of those uses for companion animals. Finally, pets are not a single “human-like” model: species, breed, age, size, and physiology differ substantially, while in human nutrition we are more accustomed to reasoning within one species (even if we still sometimes underestimate differences by sex, population, or ethnicity).

 1B) Species-specific research is essential. Human data and in vitro work can be valuable starting points, especially to build mechanistic plausibility, but translation must be handled with caution.

In human health, animal data have long been used as a preparatory step before human studies, and we have relatively mature scientific conventions for interpreting that direction of translation. The reverse path, starting from humans and “converting” to dogs or cats, does not have the same level of validated conversion factors and predictability, even if it is a first step of evaluation. Moreover, formulations should be built with veterinary input to ensure dosing, targets, and claims remain appropriate for the animal.

1C) Overall, I believe humanization has been a major positive driver for this category. It has pushed the market toward higher quality expectations, better ingredient scrutiny, and greater willingness to invest in products perceived as safer and more premium. That said, better-informed choices do not come from humanization alone; they also come from the fact that many “pet parents” are highly attentive buyers, sometimes even more demanding about pet nutrition than about their own.
The risk is that humanization can create unrealistic expectations if marketing language is not carefully managed.

1D) From a supplier standpoint, the critical parameters are essentially the same as in the human space, but the need for consistency is even more important because of the variability in real-life use.

• Standardization of actives is foundational: it ensures batch reproducibility and enables consistent performance at a defined dose.
• Strong GMP and quality control are non-negotiable: thorough testing, deep knowledge of the starting botanical matrices, and robust specifications.
• Bioavailability and bioaccessibility should be understood and, where possible, characterized, because without knowing how an animal can access the active fraction, it becomes difficult to set rational dosing or predict response.

In short, credible pet supplementation starts with reproducible composition, controlled quality, and informed dosing.

1E) Pet owners are strongly guided by these trends. They are increasingly informed and often actively look for finished products that are clean label and perceived as “high integrity.”
Sustainability, however, is not a single concept; it spans multiple dimensions:

• raw material sourcing and traceability;
• greener manufacturing (e.g., minimizing organic solvents, responsible process choices);
• operational practices such as water reuse and renewable energy;
• transparent documentation that supports what is being claimed.

The market is becoming more demanding, so sustainability and transparency will increasingly function as trust signals, provided they are substantiated rather than used as generic claims.

1F) A pragmatic expectation today is a stepwise evidence model. As a baseline, it would already be a meaningful improvement to see more ingredients supported by in vitro evidence demonstrating biological activity relevant to the intended use.
Beyond that, it is highly desirable to generate targeted in vivo evidence in companion animals, because the sector cannot rely indefinitely on human extrapolation. As the category matures, the demand for species-specific substantiation will inevitably increase. In short: mechanism of action is a start, but credibility will increasingly require animal-relevant data.

1G) The most misunderstood claims are usually the ones that are too generic or that blur the line between nutritional support and therapeutic effect. Consumers may easily overinterpret claims such as “for immunity,” “for cognition,” or “for mobility” as promises of treatment-level efficacy, particularly when the wording is not specific enough about the animal, condition, or expected outcome.

1H) One of the biggest challenges is ensuring statistical validity: studies must be adequately designed, powered where possible, and analyzed correctly.

Another challenge is that we still have limited shared standards on the magnitude and pattern of response to expect in many pet outcomes. For this reason, it can be valuable, where feasible, to include not only placebo but also positive controls, so that the study can anchor results against a known benchmark and improve interpretability. Finally, robust pet trials should combine objective and subjective outcomes. Ideally, study design should integrate: objective measures (e.g., blood markers or other biological indicators, where relevant), validated veterinary assessments, and structured owner-reported questionnaires.

Triangulating outcomes from these different perspectives helps produce results that are both clinically meaningful and understandable in real-world pet care.

1I) Owner-reported outcomes are valuable because owners observe day-to-day behaviour and quality-of-life changes, but emotional involvement can introduce bias and reduce objectivity. For that reason, the best practice is not choosing one over the other, it is integration. Combining owner reporting with veterinary assessment, plus rigorous controls such as a placebo (and when appropriate a positive control), increases credibility and strengthens the clinical interpretability of the results. This combined approach supports both real-world relevance and scientific robustness.

1L) Yes, definitely. Over the last two years, we have seen a clear increase in both demand and sales for ingredients positioned around healthy ageing in companion animals. A concrete example is a Vitis vinifera L. extract standardized in anthocyanins and proanthocyanidins, which has recently been incorporated into several complementary feeds (pet supplements), typically for senior dogs, with the aim of supporting cognitive health and brain performance in ageing animals. This reflects a broader market shift: healthy ageing is becoming a central platform, and brands are actively looking for ingredients with a stronger rationale and more credible evidence. 

4A) In the next 5–10 years, credibility will be determined by the ability to demonstrate serious formulation work supported by pet-relevant scientific evidence, alongside measurable and reproducible ingredient quality.

At the same time, the sector will need to substantiate “clean label,” sustainability, and transparency claims to avoid falling into the broader issue of greenwashing, which is already damaging trust across multiple categories. Ultimately, consistent quality plus credible substantiation will be the base for building long-term trust with increasingly informed pet owners.

4B) If I had to choose one single change, it would be a stronger and more standardized foundation of scientific substantiation, with clear expectations around study design, endpoints, and transparency. When companies can demonstrate ingredient quality and formulation seriousness through well-communicated evidence, rather than relying on generic claims, consumer trust increases naturally. In my view, scientific rigor is the most direct lever because it supports both credible claims and responsible education.